• Earlier in March 2026, Pfizer reported positive Phase 2 results for its investigational trispecific antibody tilrekimig in adults with moderate to severe atopic dermatitis, showing statistically significant EASI-75 responses versus placebo with a favorable safety profile across multiple monthly dosing regimens.
• The data suggest tilrekimig could emerge as a differentiated, once-monthly option across several Type 2 inflammatory diseases, reinforcing Pfizer’s push into higher-value immunology biologics at a time when its portfolio is transitioning beyond COVID-related products.
• We’ll now examine how tilrekimig’s encouraging Phase 2 efficacy and safety profile may influence Pfizer’s investment narrative and longer-term outlook.

Uncover the next big thing with 33 elite penny stocks that balance risk and reward.

Pfizer Investment Narrative Recap

To own Pfizer today, you need to believe its pivot from COVID products toward higher-value biologics, oncology and immunology can eventually offset patent losses and policy pressure on drug pricing. Tilrekimig’s positive Phase 2 eczema data adds another early proof point to that transition, but it does not change the near term focus on managing a high payout ratio and concerns that earnings and cash flow may not fully cover the current dividend.

The tilrekimig update sits alongside other recent pipeline wins, such as the Phase 3 EV-304 results for PADCEV plus Keytruda in muscle-invasive bladder cancer, which highlight Pfizer’s push into complex biologics and oncology combinations. Together, these announcements feed into the key catalyst of pipeline execution at a time when analysts are watching to see whether new launches can meaningfully replace revenue from products facing loss of exclusivity.

Yet while the science looks encouraging, investors should be aware of the growing questions around dividend sustainability and cash coverage of payouts...

Pfizer’s narrative projects $59.6 billion revenue and $12.8 billion earnings by 2028. This implies revenues declining by 2.2% per year and an earnings increase of about $2.1 billion from $10.7 billion today.

Uncover how Pfizer's forecasts yield a $29.08 fair value, a 7% upside to its current price.

Exploring Other Perspectives

While consensus sees modest revenue decline, some bullish analysts expected about US$65.5 billion of sales and US$15.1 billion of earnings by 2028, so tilrekimig’s progress could either support or challenge those more optimistic views depending on how the broader pipeline and pricing risks evolve.

Explore 28 other fair value estimates on Pfizer - why the stock might be worth 8% less than the current price!

Decide For Yourself

Disagree with existing narratives? Extraordinary investment returns rarely come from following the herd, so go with your instincts.

• A great starting point for your Pfizer research is our analysis highlighting 1 key reward and 4 important warning signs that could impact your investment decision.
• Our free Pfizer research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate Pfizer's overall financial health at a glance.

Curious About Other Options?

Don't miss your shot at the next 10-bagger. Our latest stock picks just dropped:

• Find 50 companies with promising cash flow potential yet trading below their fair value.
• The latest GPUs need a type of rare earth metal called Terbium and there are only 29 companies in the world exploring or producing it. Find the list for free.
• Capitalize on the AI infrastructure supercycle with our selection of the 34 best 'picks and shovels' of the AI gold rush converting record-breaking demand into massive cash flow.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.